- Home
- CHRS vs PRQR Comparison
CHRS vs PRQR Comparison
Compare CHRS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PRQR
- Stock Information
- Founded
- CHRS 2010
- PRQR 2012
- Country
- CHRS United States
- PRQR Netherlands
- Employees
- CHRS N/A
- PRQR N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- PRQR Health Care
- Exchange
- CHRS Nasdaq
- PRQR Nasdaq
- Market Cap
- CHRS 194.1M
- PRQR 224.4M
- IPO Year
- CHRS 2014
- PRQR 2014
- Fundamental
- Price
- CHRS $1.70
- PRQR $2.72
- Analyst Decision
- CHRS Strong Buy
- PRQR Strong Buy
- Analyst Count
- CHRS 4
- PRQR 8
- Target Price
- CHRS $4.51
- PRQR $8.88
- AVG Volume (30 Days)
- CHRS 1.0M
- PRQR 637.0K
- Earning Date
- CHRS 11-07-2025
- PRQR 11-07-2025
- Dividend Yield
- CHRS N/A
- PRQR N/A
- EPS Growth
- CHRS N/A
- PRQR N/A
- EPS
- CHRS 1.55
- PRQR N/A
- Revenue
- CHRS $272,209,000.00
- PRQR $20,129,184.00
- Revenue This Year
- CHRS N/A
- PRQR N/A
- Revenue Next Year
- CHRS $109.48
- PRQR N/A
- P/E Ratio
- CHRS $3.38
- PRQR N/A
- Revenue Growth
- CHRS 52.33
- PRQR 8.65
- 52 Week Low
- CHRS $0.66
- PRQR $1.07
- 52 Week High
- CHRS $2.43
- PRQR $4.21
- Technical
- Relative Strength Index (RSI)
- CHRS 54.43
- PRQR 54.91
- Support Level
- CHRS $1.64
- PRQR $2.61
- Resistance Level
- CHRS $1.81
- PRQR $3.00
- Average True Range (ATR)
- CHRS 0.10
- PRQR 0.25
- MACD
- CHRS -0.02
- PRQR -0.01
- Stochastic Oscillator
- CHRS 42.32
- PRQR 57.78
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.